Abstract

The unprecedented success of COVID-19 vaccine development has transformed not only infectious disease control but also revealed unexpected implications for cancer immunotherapy. Emerging preclinical and clinical evidence suggests that SARS-CoV-2 vaccines, particularly mRNA-based platforms, can enhance antitumor immunity through mechanisms that overlap with immune checkpoint blockade and cancer vaccination. These vaccines activate dendritic cells, induce interferon signalling, and prime cytotoxic CD8⁺ T lymphocytes, the key mediators of tumor regression and immune reprogramming. Reports of spontaneous tumor regression, improved immunotherapy outcomes, and increased rogression-free survival in vaccinated cancer patients underscore the immunomodulatory potential of COVID-19 vaccination. Moreover, studies demonstrate that mRNA vaccines can reshape the tumor microenvironment, converting “cold” tumors into “hot” immune-responsive phenotypes via enhanced antigen presentation and trained innate immunity. While these findings herald a new frontier in oncoimmunology, variability in vaccine responsiveness among different cancer types and treatment regimens warrants cautious optimism. The integration of vaccine induced immune modulation with established and emerging immunotherapeutic strategies could redefine the landscape of precision oncology. Ultimately, the pandemic’s legacy extends beyond viral containment offering a translational blueprint for harnessing vaccine platforms in cancer prevention and therapy.

• 1.   Cook N.L., Lauer M.S. Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. NAM Perspect. 2021 Jul 26; 2021: 10.31478/202107e. doi: 10.31478/202107e.
• 2.   Aghila Rani K.G., Hamad M.A., Zaher D.M., Sieburth S.M., Madani N., Al-Tel T.H. Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges. Expert Opin117 IJPRP / Volume 15 Number 2 May – August 2026 Drug Discov. 2021 Apr; 16(4): 365-371. doi: 10.1080/17460441.2021.1854221.
• 3.   Karimi-Maleh H., Dragoi E.N., Lichtfouse E. How the COVID-19 pandemic has changed research? Environ Chem Lett. 2022 Dec 29: 1-4. doi: 10.1007/s10311-022-01536-4.
• 4.   Sousa L.G., McGrail D.J., Li K., MarquesPiubelli M.L., Gonzalez C., Dai H. et al. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 2022 Mar; 10(3): e004371. doi: 10.1136/jitc- 2021-004371.
• 5.   Qian Y., Zhu Z., Mo Y.Y., Zhang Z. COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study. Infect Agent Cancer. 2023 Sep 7; 18(1): 50. doi: 10.1186/s13027-023-00526-7.
• 6.   Arunachalam A.B., Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits. Vaccines (Basel). 2024 Apr 9; 12(4): 396. doi: 10.3390/vaccines12040396. .
• 7.   Hellgren F., Rosdahl A., Arcoverde Cerveira R., Lenart K., Ols S., Gwon Y.D. et al. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans. JCI Insight. 2024 May 8; 9(9): e175401. doi: 10.1172/jci.insight.175401.
• 8.   Oloruntimehin S., Akinyi F., Paul M., Ariyo O. mRNA Vaccine Technology Beyond COVID-19. Vaccines (Basel). 2025 May 31; 13(6): 601. doi: 10.3390/vaccines13060601.
• 10.   Grippin A.J., Marconi C., Copling S., Li N., Braun C., Woody C. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025 Oct 22; [Epub ahead of print]. doi:10.1038/s41586-025- 09655-y.
• 11.   Tufail M., Jiang C.H., Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025 Jul 31; 10(1): 227. doi: 10.1038/s41392-025-02280-1.
• 12.   Senba M., Mori N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev. 2012 Oct 5; 6(2): e17. doi: 10.4081/oncol.2012.e17.
• 13.   Wang D., DuBois R.N. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015 Oct; 36(10): 1085-93. doi: 10.1093/carcin/ bgv123.
• 14.   Yenyuwadee S., Aliazis K., Wang Q., Christofides A., Shah R., Patsoukis N. et al. Immune cellular components and signaling pathways in the tumor microenvironment. Semin Cancer Biol. 2022 Nov; 86(Pt 2): 187-201. doi: 10.1016/j.semcancer.2022.08.004.
• 15.   Bergamaschi C., Terpos E., Rosati M., Angel M., Bear J., Stellas D. et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 Aug 10; 36(6): 109504. doi: 10.1016/j. celrep.2021.109504.
• 16.   Mehrani Y., Morovati S., Keivan F., Sarmadi S., Shojaei S., Forouzanpour D. et al. Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on AntiTumor Efficacy. Cells. 2025 May 30; 14(11): 812. doi: 10.3390/cells14110812.
• 17.   Yatim N., Boussier J., Tetu P., Smith N., Bruel T., Charbit B. et al. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Sci Adv. 2021 Aug 18; 7(34): eabg4081. doi: 10.1126/sciadv.abg4081.
• 18.   Li S., Zou Y., McMasters A., Chen F., Yan J. Trained immunity: A new player in cancer immunotherapy. Elife. 2025 Jun 18; 14: e104920. doi: 10.7554/eLife.104920.
• 19.   Sui Y., Berzofsky J.A. Trained immunity inducers in cancer immunotherapy. Front Immunol. 2024 Jul 16; 15: 1427443. doi: 10.3389/ fimmu.2024.1427443.]
• 20.   Idiiatullina E., Parker D. Trained immunity in the lung. Elife. 2025 Aug 1; 14: e104918. doi: 10.7554/eLife.104918.
• 21.   Simonis A., Theobald S.J., Koch A.E., Mummadavarapu R., Mudler J.M., Pouikli A et al. Persistent epigenetic memory of SARSCoV-2 mRNA vaccination in monocyte-derived macrophages. Mol Syst Biol. 2025 Apr; 21(4): 341-360. doi: 10.1038/s44320-025-00093-6.
• 22.   Kim S., Jeon J.H., Kim M., Lee Y., Hwang Y.H., Park M. et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site. Durre Aden, Sufian Zaheer. COVID-19 Vaccines: Bolstering Cancer Treatment.118 Indian Journal of Pathology: Research and Practics IJPRP / Volume 15 Number 2 May – August 2026 Nat Commun. 2024 Aug 27; 15(1): 7226. doi: 10.1038/s41467-024-51411-9.
• 24.   Khawaja F., Angelidakis G., Feldman A., Ravi V., Woodman E., Bhatti M. et al. COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic. Cancer Med. 2023 Dec; 12(24): 22006-22022. doi: 10.1002/ cam4.6781.
• 25.   Ospina A.V., Brugés R., Triana I., SánchezVanegas G., Barrero A., Mantilla W. et al. Impact of vaccination against COVID-19 on patients with cancer in ACHOC-C19 study: Real world evidence from one Latin American country. J Cancer. 2023 Jul 31; 14(13): 2410- 2416. doi: 10.7150/jca.79969.
• 26.   Boehm D.T., Landreth K.M., Kilic E.S., Lee K.S., Misra B., Bobbala S. et al. Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice. Sci Rep. 2025 Feb 13; 15(1): 5337. doi: 10.1038/s41598- 025-89930-0.
• 27.   Jaber N.F., Paoli J., Jerkovic S.G. Rapid regression of multiple melanocytic nevi in an individual with history of melanoma with the CDKN2A mutation. JAAD Case Rep. 2023 Jun 20; 38: 113-116. doi: 10.1016/j.jdcr.2023.06.019.
• 28.   Wesselmann U., Kvasnicka HM., Bozkurt A., Wieland U., Hofmann S.C. Long lasting complete regression of a metastatic polyomavirus-positive Merkel cell carcinoma after COVID-19 booster vaccination. Eur J Cancer. 2024 Dec; 210: 275. doi: 10.1016/j. ejca.2024.210275.
• 29.   Gambichler T., Boms S., Hessam S., Tischoff I., Tannapfel A., Lüttringhaus T. et al. Primary cutaneous anaplastic large-cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination. Br J Dermatol. 2021 Dec; 185(6): 1259-1262. doi: 10.1111/bjd.20630.
• 30.   Aouali S., Benkaraache M., Almheirat Y., Zizi N., Dikhaye S. Complete remission of primary cutaneous follicle centre cell lymphoma associated with COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022 Sep; 36(9): e676-e678. doi: 10.1111/jdv.18246.
• 31.   Tan J.L. COVID-19 induced remission of biliary and renal cell carcinomas. J Clin Oncol. 2023; 41(16_suppl): e14598. doi: 10.1200/ JCO.2023.41.16_suppl.e14598.
• 32.   Yitbarek K., Abraham G., Girma T., Tilahun T., Woldie M. The effect of Bacillus CalmetteGuérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic. Vaccine. 2020 Sep 22; 38(41): 6374-6380. doi: 10.1016/j.vaccine.2020.08.018.
• 33.   Jurczak M., Kaczmarek J., KowalewskaPietrzak M., Stelmach P., Druszczynska M. NOD2 (Nucleotide-Binding Oligomerization Domain-Containing Protein 2)-Mediated Modulation of the Immune Response Induced by BCG (Bacillus Calmette-Guérin) Bacilli. Pathogens. 2025 Jul 11; 14(7): 683. doi: 10.3390/ pathogens14070683.
• 34.   Daniels P., Cassoday S., Gupta K., Giurini E., Leifheit M.E., Zloza A. et al. Intratumoral Influenza Vaccine Administration Attenuates Breast Cancer Growth and Restructures the Tumor Microenvironment through Sialic Acid Binding of Vaccine Hemagglutinin. Int J Mol Sci. 2023 Dec 22; 25(1): 225. doi: 10.3390/ ijms25010225.
• 35.   NIH Research Matters. An mRNA vaccine to treat pancreatic cancer. National Institutes of Health; 2023 May 23. Available from: https:// www.nih.gov/news-events/nih-researchmatters/mrna-vaccine-treat-pancreatic-cancer.
• 36.   Latifyan S., Haanen J.B. Melanoma neoantigen vaccines: Are we getting more personal now? Med. 2024 Apr 12; 5(4): 288-290. doi: 10.1016/j. medj.2024.03.004.
• 37.   Rojas L.A., Sethna Z., Soares K.C., et al. Personalized RNA neoantigen vaccines stimulate T. cells in pancreatic cancer. Nature. 2023 Jun; 618(7963): 144-150. doi: 10.1038/ s41586-023-06063-y.
• 38.   Sahin U., Derhovanessian E., Miller M., Kloke B.P., Simon P., Löwer M. et al. Personalized RNA mutanome vaccines mobilize polyspecific therapeutic immunity against cancer. Nature. 2017 Jul 13; 547(7662): 222-226. doi: 10.1038/nature23003.
• 39.   Haanen J., Ernstoff M.S., Wang Y., Menzies A.M., Puzanov I., Grivas P. et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020 Jun; 31(6): 724-744. doi: 10.1016/j.annonc.2020.03.285.
• 40.   Jaber N. Study details long-term side effects of immune checkpoint inhibitors. Cancer Currents119 IJPRP / Volume 15 Number 2 May – August 2026 Blog. National Cancer Institute; 2021 Apr 30. Available from: https://www.cancer.gov/ news-events/cancer-currents-blog/2021/ immune-checkpoint-inhibitors-melanomalong-term-side-effects.
• 41.   Liu Z., Zhu Y., Xie H., Zou Z. Immunemediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. 2023 Jan 9; 13: 1077468. doi: 10.3389/fphar.2022.1077468.
• 42.   Hoerger M., Gerhart J., Swartz M.C. Variability in COVID-19 Vaccine Response Among People with Cancer: What Health Care Strategy Best Protects the Vulnerable? JAMA Oncol. 2023 Feb 1; 9(2): 177-179. doi: 10.1001/ jamaoncol.2022.5874.
• 43.   Lee L.Y.W., Tilby M., Starkey T., Ionescu M.C., Burnett A., Hattersley R. et al. Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response with Infection Severity in Patients with Cancer: A National COVID Cancer Cross-sectional Evaluation. JAMA Oncol. 2023 Feb 1; 9(2): 188-196. doi: 10.1001/ jamaoncol.2022.597

Data Sharing Statement

Funding